Cutaneous Melanoma

Oncology·MeSH: Melanoma

Prevalence

75.0 / 100K

Incidence

23.0 / 100K/yr

25 drugs in development·10 companies·15 clinical trials

Drug Pipeline by Phase

Phase 3(17)

Drug	Company
Cabozantinib S-malate	Royalty Pharma plc (RPRX)
dabrafenib	GH Research PLC (GHRS)
Dacarbazine	ENANTA PHARMACEUTICALS INC (ENTA)
Dacarbazine	Filana Therapeutics Inc. (FLNA)
IMA203	Filana Therapeutics Inc. (FLNA)
IMA203	Merus N.V. (MRUS)
IMA203	PTC THERAPEUTICS, INC. (PTCT)
IMA203	ENANTA PHARMACEUTICALS INC (ENTA)
LHRH Agonist	Crinetics Pharmaceuticals, Inc. (CRNX)
lifileucel	PTC THERAPEUTICS, INC. (PTCT)
lifileucel	ENANTA PHARMACEUTICALS INC (ENTA)
lifileucel	Merus N.V. (MRUS)
lifileucel	Filana Therapeutics Inc. (FLNA)
nemvaleukin alfa	Mural Oncology plc (MURA)
nemvaleukin alfa intravenous less frequent dosing	Mural Oncology plc (MURA)
temozolomide	ENANTA PHARMACEUTICALS INC (ENTA)
trametinib dimethyl sulf	GH Research PLC (GHRS)

Phase 2(6)

Drug	Company
Cabozantinib S-malate	ENANTA PHARMACEUTICALS INC (ENTA)
hydroxychloroquine	GH Research PLC (GHRS)
rtx-224	Rubius Therapeutics, Inc. (RUBY)
Sargramostim	Filana Therapeutics Inc. (FLNA)
Sargramostim	ENANTA PHARMACEUTICALS INC (ENTA)
VLP-encapsulated TLR9 Agonist CMP-001	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 1(1)

Drug	Company
pf-08046049	PFIZER INC (PFE)

Preclinical(1)

Drug	Company
SST3 Agonist Program	Crinetics Pharmaceuticals, Inc. (CRNX)

BioSniper tracks 25 drugs in development for Cutaneous Melanoma across 10 companies.

There are 15 clinical trials targeting Cutaneous Melanoma tracked by BioSniper.

The estimated prevalence of Cutaneous Melanoma is approximately 75.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.